800-872-2273

Clinical Trials and Studies

Your participation matters. Help us discover and cure!

Contact us at (800) USC-CARE (800-872-2273)

We're sorry, but this trial is no longer enrolling volunteers.

A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)

Description

Brief Summary
The purpose of the study is to evaluate safety and efficacy of AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer.


Detailed Description
This is a 3-part phase 1-2 study in patients with anaplastic lymphoma kinase (ALK) + or other potentially crizotinib-sensitive NSCLC who have been receiving crizotinib. Part A is a single-arm, Phase 1, open-label, dose escalation design in patients with NSCLC who have already been receiving crizotinib for at least 8 weeks and continue to tolerate therapy. Part B is a Phase 2, open-label, randomized continuation design comparing crizotinib alone versus the combination of crizotinib + AT13387 at the maximum tolerated dose established in Part A. Part C is an open-label, randomized, Phase 2, Simon's 2 stage design evaluating single agent AT13387 or combination AT13387 + crizotinib at the MTD established in Part A in patients who progressed on crizotinib at any time.

Phase

Phase 1/2 - for trials that are a combination of phases 1 and 2.

Inclusion and Exclusion Criteria

  • Men or women 18 years of age or older
  • Must have Non-small Cell Lung Cancer with ALK+ mutation or other mutations or rearrangements potentially sensitive to crizotinib
  • Measurable disease
  • Must have been receiving or have received crizotinib
  • Have adequate cardiac, bone marrow, liver and kidney function
  • Must be willing and able to provide written informed consent and comply with the protocol and study procedures

  • Prior anti-cancer treatment with any HSP90 inhibitor
  • Have received chemotherapy, radiation therapy or other anticancer treatment other than crizotinib within 3 weeks prior to the first dose of study drug
  • Prior malignancy other than adequately treated basal or squamous cell carcinoma of the skin, superficial bladder cancer, low-grade cervical cancer, non-metastatic prostate cancer, or have been disease-free for at least 3 years
  • Abnormal heart function
  • Presence of a life-threatening illness, medical condition, organ system dysfunction, or other factors
  • Hypersensitivity of AT13387 or other components of the drug product
  • Treatment with an investigational drug within 3 weeks prior to the first dose of study drug
  • Severe systemic diseases or active uncontrolled infections
  • Known history of human immunodeficiency virus (HIV) or seropositive test for hepatitis C virus or hepatitis B virus

Sites

  • California

    • USC Norris Comprehensive Cancer Center, Los Angeles, California, 90033
    • Innovative Clinical Research Institute, Whittier, California, 90603
    • UCLA Medical Center, Santa Monica, California, 90404
    • UCLA Medical Center, Los Angeles, California, 90095
    • Sharp Clinical Oncology Research-Sharp Memorial Hospital, San Diego, California, 92123

  • Arizona

    • Mayo Clinic-Scottsdale, Scottsdale, Arizona, 85259
    • Mayo Clinic-Scottsdale, Scottsdale, Arizona, 85259

  • Oregon

    • Providence Portland Medical Center, Portland, Oregon, 97213

  • Washington

    • Swedish Cancer Institute, Seattle, Washington, 98104
    • University of Washington Medical Center, Seattle, Washington, 98109
    • University of Washington Medical Center, Seattle, Washington, 98109

  • Texas

    • University of Texas Southwestern Medical Center, Dallas, Texas, 75390

  • Nebraska

    • University of Nebraska Medical Center Eppley Cancer Center, Omaha, Nebraska, 68198

  • Minnesota

    • Mayo Clinic-Rochester, Rochester, Minnesota, 55905

  • Missouri

    • Washington University School of Medicine, St. Louis, Missouri, 63110

  • Tennessee

    • The West Clinic, Memphis, Tennessee, 38120
    • Sarah Cannon Research Institute, Nashville, Tennessee, 37203

  • Wisconsin

    • University of Wisconsin-Carbone Cancer Center, Madison, Wisconsin, 53579

  • Illinois

    • University of Chicago, Chicago, Illinois, 60637
    • Northwestern University The Feinberg School of Medicine, Chicago, Illinois, 60611

  • Indiana

    • Indiana University Melvin and and Bren Simon Cancer Center, Indianapolis, Indiana, 46202

  • Ohio

    • University of Cincinnati Cancer Institute, Cincinnati, Ohio, 45267
    • Oncology Hematology in Cincinnati, Cincinnati, Ohio, 45242

  • France

    • Hopital Saint Antoine, Creteil Cedex, 94010
    • Hopital Saint Antoine, Creteil Cedex, 94010
    • CHRU de Lille, Lille cedex, 59037
    • Hopital Tenon, Paris, 75020
    • Centre Hospitalier de Grenoble, Grenoble, 38043
Powered by SC CTSI